Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s42399-020-00631-3 http://scihub22266oqcxt.onion/10.1007/s42399-020-00631-3 33173850!7646222!33173850     free     free     free       SN+Compr+Clin+Med 2020 ; 2 (12): 2726-2729 Nephropedia Template TP {{tp|p=33173850|t=2020. NAFLD and COVID-19: a Pooled Analysis |pdf=|usr=}}{{33173850}} gab.com Text NAFLD and COVID-19: a Pooled Analysis JO: SN Compr Clin Med http://www.kidney.de/pget.php?&tw=1&pmid=33173850 #FOAvip The earliest evidence from China suggested that COVID-19 patients are even more vulnerable to succumbing from complications in the presence of a multimorbid status, including metabolic syndrome. Due to ongoing metabolic abnormalities, non-alcoholic fatty liver disease (NAFLD) appears to be a potential risk factor for contracting SARS-CoV-2 infection and developing related complications. This is because of the interplay of chronically active inflammatory pathways in NAFLD- and COVID-19-associated acute cytokine storm. The risk of severe disease could also be attributed to compromised liver function as a result of NAFLD. We systematically reviewed current literature to ascertain the relationship between NAFLD and severe COVID-19, independent of obesity, which is considered the major factor risk factor for both NAFLD and COVID-19. We found that NAFLD is a predictor of severe COVID-19, even after adjusting for the presence of obesity (OR 2.358; 95% CI: 1.902-2.923, p < 0.001). Twit Text FOAVip NAFLD and COVID-19: a Pooled Analysis ????SN Compr Clin Med http://www.kidney.de/pget.php?&tw=1&pmid=33173850 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33173850 #FOAvip English Wikipedia <ref>{{Cite pmid|33173850}}</ref> NAFLD and COVID-19: a Pooled Analysis #MMPMID33173850 Sachdeva S; Khandait H; Kopel J; Aloysius MM; Desai R; Goyal H SN Compr Clin Med 2020[]; 2 (12): 2726-2729 PMID33173850show ga The earliest evidence from China suggested that COVID-19 patients are even more vulnerable to succumbing from complications in the presence of a multimorbid status, including metabolic syndrome. Due to ongoing metabolic abnormalities, non-alcoholic fatty liver disease (NAFLD) appears to be a potential risk factor for contracting SARS-CoV-2 infection and developing related complications. This is because of the interplay of chronically active inflammatory pathways in NAFLD- and COVID-19-associated acute cytokine storm. The risk of severe disease could also be attributed to compromised liver function as a result of NAFLD. We systematically reviewed current literature to ascertain the relationship between NAFLD and severe COVID-19, independent of obesity, which is considered the major factor risk factor for both NAFLD and COVID-19. We found that NAFLD is a predictor of severe COVID-19, even after adjusting for the presence of obesity (OR 2.358; 95% CI: 1.902-2.923, p < 0.001). äNAFLD and COVID-19: a Pooled Analysis (epmc).pdf DeepDyve Pubget Overpricing